• Sovaldi, Research, Genomic Revolution, Thematic Investing, ARK Invest

    A Bitter Pill: The High Cost of Sovaldi

    by | Health
    Mentioned Companies: ABBV, CVS, ESRX, GILD

    It’s almost impossible to imagine a pharma company giving up on a patent. The impossible can happen, as it did in August 2014, when Vertex Pharmaceuticals gave up on Incivek, its flagship hepatitis C treatment. “This decision has been taken in view of available alternative treatments and the diminishing market demand for Incivek,” read a […]